

**Prognostic Value of Long Noncoding RNA NORAD in Various cancers: a meta-analysis**

Qin Yang <sup>a, b, 1</sup>, Zheng Zhang <sup>c, 1</sup>, Yuan-Yuan Gong <sup>a, b, 1</sup>, Zhi-Ran Li <sup>a, b</sup>, Hua-Zhu

Zhang <sup>a, b</sup>, Gong-Hao He <sup>a, b, \*</sup>

*<sup>a</sup> Research Center of Clinical Pharmacology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming 650032, China.*

*<sup>b</sup> Department of Pharmacy, 920th Hospital of Joint Logistics Support Force, 212 Dagan Rd., Kunming 650032, China.*

*<sup>c</sup> Medical Engineering Section, The 306th Hospital of PLA, Beijing 100101, China.*


**Running title:** lncRNA NORAD with prognosis of cancer patients

---

<sup>1</sup> These authors contributed equally to this work.

\* Correspondence to: Gong-Hao He, Ph.D., 212 Dagan Rd, Kunming 650032, China.

Tel: +86-871-64774793, E-mail: gonghow@hotmail.com.



**Supplementary Figure S3.** Survival curves of NORAD in various types of cancers from TCGA database. (a) The overall survival curve of patients with diverse cancers; (b) The disease-free survival curve of patients with diverse cancers.